New data from the phase III PACIFIC trial of durvalumab in patients with stage 
III non-small cell lung cancer show that the drug increases the odds of 
surviving for 24 months. The study also confirms that progression-free survival 
and time to death or distant metastasis are longer for patients treated with 
durvalumab than for patients who received a placebo.